World's Best Scientists 2026 revealed!
Francesco Passamonti

Francesco Passamonti

D-Index & Metrics

Medicine

D-Index
98
Citations
45782
World Ranking
8794
National Ranking
299

Francesco Passamonti publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Francesco Passamonti sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 548 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Francesco Passamonti D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Francesco Passamonti sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Francesco Passamonti is affiliated with the University of Milan in Italy and has contributed extensively to the field of medicine, with a focus on hematology and oncology. Their research primarily centers on myeloproliferative neoplasms and related hematological conditions.

They have authored and co-authored several significant papers, including:

  • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data, 2022, Blood
  • Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study, 2020, The Lancet Haematology
  • COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA), 2021, Journal of Hematology & Oncology
  • Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes, 2021, Journal of Clinical Oncology
  • Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study, 2023, The Lancet

Frequent co-authors in their research include:

  • Alessandro M. Vannucchi
  • Claire Harrison
  • Jean-Jacques Kiladjian
  • Barbara Mora
  • Ruben A. Mesa

Their publications are often featured in specialized venues such as:

  • Blood
  • HemaSphere
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances
  • Hematological Oncology

Passamonti's work covers multiple subfields of study within medicine, including:

  • Genetics
  • Hematology
  • Oncology
  • Molecular Biology
  • Infectious Diseases

The main topics of their research encompass:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Kruppel-like factors research
  • Chronic Lymphocytic Leukemia Research
  • Eosinophilic Disorders and Syndromes
  • Hemoglobinopathies and Related Disorders

Best Publications

  • A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders

    Robert Kralovics;Francesco Passamonti;Andreas S. Buser;Soon Siong Teo

  • New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

    Francisco Cervantes;Brigitte Dupriez;Arturo Pereira;Francesco Passamonti

  • DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

    Naseema Gangat;Domenica Caramazza;Rakhee Vaidya;Geeta George

  • Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making

    Luca Malcovati;Matteo Giovanni Della Porta;Cristiana Pascutto;Rosangela Invernizzi

  • Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

    Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes

  • Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

    Alessandro M. Vannucchi;Jean Jacques Kiladjian;Martin Griesshammer;Tamas Masszi

  • A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

    Francesco Passamonti;Francisco Cervantes;Alessandro Maria Vannucchi;Enrica Morra

  • Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study

    A Tefferi;E Rumi;G Finazzi;H Gisslinger

  • Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)

    Tiziano Barbui;Guido Finazzi;Alessandra Carobbio;Juergen Thiele

  • CALR vs JAK2 vs MPL -mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

    A Tefferi;T L Lasho;C M Finke;R A Knudson

  • Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

    Francesco Passamonti;Elisa Rumi;Ester Pungolino;Lucia Malabarba

  • Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

    Tiziano Barbui;Juergen Thiele;Francesco Passamonti;Elisa Rumi

  • Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.

    Francesco Passamonti;Chiara Cattaneo;Luca Arcaini;Riccardo Bruna

  • Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet

    Tiziano Barbui;Ayalew Tefferi;Alessandro M. Vannucchi;Francesco Passamonti

  • MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.

    Paola Guglielmelli;Terra L. Lasho;Giada Rotunno;Mythri Mudireddy

  • Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.

    Alessandra Carobbio;Juergen Thiele;Francesco Passamonti;Elisa Rumi

  • Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

    Robyn M. Emanuel;Amylou C. Dueck;Holly L. Geyer;Jean Jacques Kiladjian

  • Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

    Animesh Pardanani;Claire Harrison;Jorge E. Cortes;Francisco Cervantes

  • Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

    Francisco Cervantes;Alessandro M. Vannucchi;Jean Jacques Kiladjian;Haifa Kathrin Al-Ali

  • Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

    G. Barosi;R. A. Mesa;J. Thiele;F. Cervantes

Frequent Co-Authors

Alessandro M. Vannucchi
Alessandro M. Vannucchi University of Florence
Mario Cazzola
Mario Cazzola University of Pavia
Tiziano Barbui
Tiziano Barbui FROM-Fondazione per la Ricerca Ospedale di Bergamo
Claire N. Harrison
Claire N. Harrison Guy's and St Thomas' NHS Foundation Trust
Francisco Cervantes
Francisco Cervantes University of Barcelona
Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio
Alessandro Rambaldi
Alessandro Rambaldi University of Milan
Daniela Pietra
Daniela Pietra University of Pavia
Ayalew Tefferi
Ayalew Tefferi Mayo Clinic
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are considering a career in medicine but want alternate pathways or flexibility, there are a range of online healthcare degrees that offer different routes into the profession. Many students opt for nursing-related programs, which can be a more accessible starting point before advancing to higher medical roles.

For those with a Master of Science in Nursing (MSN) looking to elevate their credentials quickly, fastest msn to dnp program options provide an accelerated track to a Doctor of Nursing Practice. If affordability is your main concern, cheapest dnp programs can help you reach your goals without heavy financial burdens.

Alternatively, for those seeking entry-level positions, lpn online programs offer fast-track training to become a Licensed Practical Nurse—a crucial stepping stone in healthcare. If your interest lies in mental health, online msn pmhnp programs prepare you for specialized and in-demand roles as a Psychiatric Mental Health Nurse Practitioner.

These online pathways offer greater flexibility and can serve as valuable alternatives or stepping stones for anyone aiming for a medical career in the USA.

Best Scientists Citing Francesco Passamonti

Trending Scientists

Recently Published Articles